無料プレビュー

COMPASS Pathways plc (CMPS) · NASDAQ Global Select

プロフィール

COMPASS Pathways is a biotechnology company developing COMP360, a proprietary pharmaceutical-grade psilocybin formulation for treating serious mental health conditions. The company focuses on treatment-resistant depression as its primary indication, with clinical development in post-traumatic stress disorder and anorexia nervosa. COMPASS retains global development and commercialization rights for COMP360 and intends to commercialize in the U.S. through its own sales and marketing capabilities, with potential partnerships in select international markets.

主要指標

株価: $11.47 (-1.88%)
時価総額: 15億ドル
PER（今期予想）: -5.1
PBR: 12.7
配当利回り: —
52週レンジ: $4.88 – $15.87
業種: Healthcare / Biotechnology
上場: NASDAQ Global Select
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG、ALNY Alnylam Pharmaceuticals, Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-03 · 更新: 2026-10-09